SNP88 is independent of Tyrer-Cuzick model; improved prediction when combined multiplicatively
FRIDAY, Dec. 30, 2016 (HealthDay News) — A panel of 88 single nucleotide polymorphisms (SNPs) can predict breast cancer risk, according to a study published online Dec. 28 in the Journal of Clinical Oncology.
Jack Cuzick, Ph.D., from the Queen Mary University of London , and colleagues examined a risk score on the basis of 88 SNPs (SNP88) in a nested case-control study of women enrolled in the International Breast Intervention Study or the Royal Marsden study. Three hundred fifty-nine women who developed cancer were matched to 636 controls by age, trial, follow-up time, and treatment arm. Matched concordance indices were used to assess performance of SNP88 alone and with other breast cancer risk factors assessed using the Tyrer-Cuzick (TC) model.
The researchers found that SNP88 predicted breast cancer risk overall (interquartile range odds ratio [IQ-OR], 1.37), primarily for estrogen receptor-positive disease versus estrogen receptor-negative disease (IQ-OR, 1.44). For SNP88, the observed risk was 46 percent of expected. There was no significant interaction for treatment arm (P for heterogeneity = 0.5). The predictive power was similar to that of the TC model (IQ-OR, 1.45); SNP88 was found to be independent of TC (P = 0.7). There was a substantial improvement when SNP88 and TC were combined multiplicatively (IQ-OR, 1.64).
“A polygenic risk score may be used to refine risk from the TC or similar models in women who are at an elevated risk of breast cancer and considering preventive therapy,” the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry; two authors disclosed royalty payments for commercial use of the Tyrer-Cuzick algorithm.
Copyright © 2016 HealthDay. All rights reserved.
